-
The
experimental HIV integrase inhibitor elvitegravir works as well as raltegravir
(Isentress) for treatment-experienced
people with extensive drug resistance, and was well tolerated overall,
according to data presented at the
sixth International AIDS Society conference (IAS 2011) this week in Rome.
Integrase ...
21 July 2011 | Liz Highleyman
-
Italian investigators have found evidence of the
transmission of HIV that is resistant to the fusion inhibitor T-20
(enfuvirtide, Fuzeon).
However, there is at yet no evidence that virus is being
transmitted that is resistant to the integrase inhibitor ...
09 February 2011 | Michael Carter
-
The European Medicines Agency has approved once-daily dosing
of the HIV protease inhibitor darunavir (Prezista)
for treatment-experienced adults without signs of potential resistance to the
drug.
Once-daily dosing of darunavir requires patients to take two
400mg tablets with 100mg of ritonavir ...
24 January 2011 | Keith Alcorn
-
The United States Food and Drug Administration has approved
new dosing for the protease inhibitor darunavir
(Prezista) that will allow the
drug to be dosed once daily for patients with prior treatment experience, provided they do not have darunavir-associated ...
14 December 2010 | Keith Alcorn
-
Outcomes for treatment-experienced patients receiving 'salvage therapy' that includes the protease inhibitor darunavir (Prezista) are equal to,
or even better, than those seen in clinical trials, Swiss investigators report
in the online edition of HIV Medicine.
After 48 weeks ...
25 October 2010 | Michael Carter
-
Darunavir/ritonavir-based antiretroviral therapy is equally
effective in treatment-experienced women and men, US investigators report in
the Annals of Internal Medicine.
However, within four weeks of the study starting, women were
more likely to withdraw from the trial than men. The ...
22 September 2010 | Michael Carter
-
People who switched from a
suppressive boosted protease inhibitor to the integrase inhibitor raltegravir (Isentress) generally maintained
undetectable viral load with improvements in blood lipid levels, according to a
pair of studies presented this week at the Eighteenth International ...
22 July 2010 | Liz Highleyman
-
Drug regulatory authorities in the US have approved once-daily dosing of Kaletra for some treatment experienced-patients.
The Food and Drug Administration (FDA) announced on April 27th that once-daily dosing of Kaletra (lopinavir/ritonavir) was an option for ...
29 April 2010 | Michael Carter
-
Patients prescribed protease inhibitor-ritonavir (PI/r) monotherapy in ‘real-world’ clinical practice achieve viral suppression rates equivalent to those seen in randomised controlled trials, according to two surveys presented to the second BHIVA/BASHH joint conference in Manchester.
Although ...
27 April 2010 | Gus Cairns
-
Gilead Sciences today announced that it has decided to abandon its research programme to develop the experimental nucleoside analogue amdoxovir (DAPD). Rights to develop the drug will pass back to Emory University and the University of ...
28 January 2004 | Keith Alcorn
Talking points: a checklist for you and your doctorTalking points is designed to help you talk to your doctor about HIV
treatment.
Preventing HIVAn essential resource providing evidence-based information on preventing HIV infection. 
HIV treatment update – Winter 201206 February 2012The new edition of HIV treatment update (HTU) is now...
A visit from Wandsworth Oasis26 January 2012On Wednesday this
week, we were delighted to have a visit...
Adventurers with HIV – a photo gallery19 January 2012Back in
November we sent out a
call for adventurous people with...